Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aeglea Bio Therapeutics Inc is a biotechnology business based in the US. Aeglea Bio Therapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea Bio Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.55 |
|---|---|
| 52-week range | $0.59 - $8.50 |
| 50-day moving average | $1.32 |
| 200-day moving average | $4.11 |
| Wall St. target price | $4.43 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5455 from 2022-06-28
| 1 week (2022-06-20) | N/A |
|---|---|
| 1 month (2022-05-31) | -65.47% |
| 3 months (2022-03-28) | N/A |
| 6 months (2021-12-31) | -88.52% |
| 1 year (2021-07-01) | -92.35% |
|---|---|
| 2 years (2020-07-01) | -94.15% |
| 3 years (2019-07-01) | 6.84 |
| 5 years (2017-06-30) | 3.85 |
| Revenue TTM | $20.1 million |
|---|---|
| Gross profit TTM | $-38,330,000 |
| Return on assets TTM | -36.41% |
| Return on equity TTM | -77.69% |
| Profit margin | 0% |
| Book value | $1.25 |
| Market capitalisation | $39.2 million |
TTM: trailing 12 months
We're not expecting Aeglea Bio Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aeglea Bio Therapeutics's shares have ranged in value from as little as $0.585 up to $8.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea Bio Therapeutics's is 1.5957. This would suggest that Aeglea Bio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.